Sponsored Links
| Adolor Corporation Expands Phase 2 Opioid Induced Constipation Program |
 |
 |
 |
| Medical News - Clinical Trials and Drug Trials | |||
|
Adolor Corporation (NasdaqGM: ADLR) announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC). The Company's first Phase 2 study of this compound initiated in October 2010 and is evaluating two doses of ADL5945 (0.10 mg and 0.25 mg) each administered twice daily in patients with OIC... Read more: Clinical Trials / Drug Trials News From Medical News Today
|